Adial Pharmaceuticals (ADIL) Non-Current Assets (2017 - 2026)
Adial Pharmaceuticals (ADIL) posted Non-Current Assets of $424373.0 for Q1 2026, down 87.65% sequentially from $3.4 million in Q4 2025, and down 87.77% YoY from $3.5 million in Q1 2025.
Adial Pharmaceuticals (ADIL) Non-Current Assets (2017 - 2026) Analysis & Trends
Adial Pharmaceuticals has reported Non-Current Assets for 10 years, with the latest figure at $424373.0 in Q1 2026.
- Quarterly Non-Current Assets fell 87.77% year-over-year to $424373.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $3.7 million (up 7.79% YoY) and the FY2025 annual result came in at $3.4 million, down 2.02% from the prior year.
- Non-Current Assets retreated to $424373.0 in Q1 2026 per ADIL's latest filing, from $3.4 million in the prior quarter.
- Over five years, Non-Current Assets peaked at $3.8 million in Q1 2024 and troughed at $424373.0 in Q1 2026.
- A 5-year average of $2.3 million and a median of $3.3 million in 2023 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2024 and 2026: Non-Current Assets soared 308.75% in 2024, then plunged 87.77% in 2026.
- Over 5 years, Non-Current Assets stood at $948392.0 in 2022, then jumped by 253.02% to $3.3 million in 2023, then grew by 4.74% to $3.5 million in 2024, then fell by 2.02% to $3.4 million in 2025, then sank by 87.65% to $424373.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $424373.0, $3.4 million, and $646015.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.59 Bn | 131.73 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 86.21 Bn | 78.22 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 65.65 Bn | 60.47 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 57.67 Bn | 52.53 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 42.10 Bn | 37.00 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 31.62 Bn | 28.31 Bn | 992.69 Mn | 938.60 Mn |
| 7 | BioNTech SE | 27.90 Bn | 9.51 Bn | 668.28 Mn | 6.80 Bn |
| 8 | Insmed | 27.51 Bn | 26.35 Bn | 358.27 Mn | 468.65 Mn |
| 9 | Royalty Pharma | 27.29 Bn | 26.45 Bn | - | 18.06 Bn |
| 10 | Adial Pharmaceuticals | 27.92 Mn | 27.92 Mn | - | 244,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 424,373.00 |
| Dec 31, 2025 | 3.44 Mn |
| Sep 30, 2025 | 646,015.00 |
| Jun 30, 2025 | 3.45 Mn |
| Mar 31, 2025 | 3.47 Mn |
| Dec 31, 2024 | 3.51 Mn |
| Sep 30, 2024 | 3.51 Mn |
| Jun 30, 2024 | 3.81 Mn |
| Mar 31, 2024 | 3.83 Mn |
| Dec 31, 2023 | 3.35 Mn |
| Sep 30, 2023 | 3.37 Mn |
| Jun 30, 2023 | 1.73 Mn |
| Mar 31, 2023 | 937,028.00 |
| Dec 31, 2022 | 948,392.00 |
| Sep 30, 2022 | 968,415.00 |
| Jun 30, 2022 | 983,677.00 |
| Mar 31, 2022 | 998,659.00 |
| Dec 31, 2021 | 1.01 Mn |
| Sep 30, 2021 | 2.46 Mn |
| Jun 30, 2021 | 2.47 Mn |